AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%
Last update at 2025-04-17T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
Tue 25 Mar 25, 11:45 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -969.24800M | -795.79800M | -407.23500M | -169.15600M | -177.49700M |
| Minority interest | - | - | - | - | - |
| Net income | -971.23300M | -796.69700M | -373.70600M | -168.33700M | -177.49700M |
| Selling general administrative | 568.28M | 490.26M | 293.80M | 132.16M | 88.30M |
| Selling and marketing expenses | 370.29M | 303.10M | 168.59M | 153.33M | 102.86M |
| Gross profit | 380.04M | 364.15M | 313.92M | 273.33M | 135.06M |
| Reconciled depreciation | 124.10M | 47.77M | 33.31M | 31.36M | 24.68M |
| Ebit | -980.40700M | -797.06400M | -412.40500M | -169.09200M | -160.54500M |
| Ebitda | -981.95600M | -793.40800M | -407.22400M | -136.38000M | -135.86600M |
| Depreciation and amortization | -1.54900M | 3.66M | 5.18M | 32.71M | 24.68M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -980.40700M | -797.06400M | -412.40500M | -169.09200M | -161.39600M |
| Other operating expenses | 1543.64M | 1304.93M | 842.31M | 550.77M | 370.26M |
| Interest expense | -11.15900M | 1.54M | 0.67M | 0.00000M | 17.95M |
| Tax provision | 1.99M | 0.90M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 9.46M | 3.46M | 6.07M | 3.66M | 15.61M |
| Net interest income | 9.46M | 1.92M | 5.40M | 2.17M | -16.61200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.99M | 0.90M | -33.52900M | -0.81900M | 1.85M |
| Total revenue | 563.24M | 507.86M | 429.90M | 381.68M | 208.87M |
| Total operating expenses | 1360.45M | 1161.21M | 726.33M | 442.43M | 296.45M |
| Cost of revenue | 183.20M | 143.72M | 115.98M | 108.34M | 73.81M |
| Total other income expense net | 11.16M | 1.27M | 5.17M | -0.06400M | 0.51M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -971.23300M | -796.69700M | -407.23500M | -169.15600M | -177.49700M |
| Net income applicable to common shares | -971.23300M | -796.69700M | -471.92300M | -334.16700M | -232.34600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1040.00M | 1587.47M | 2278.59M | 2663.03M | 847.56M |
| Intangible assets | 0.96M | 0.16M | 5.15M | 3.46M | 0.34M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.80M | 51.46M | 60.28M | 57.33M | 1.33M |
| Total liab | 271.59M | 429.13M | 433.28M | 242.02M | 1739.05M |
| Total stockholder equity | 768.41M | 1158.34M | 1845.31M | 2421.00M | -891.49400M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 104.94M | 173.83M | 127.89M | 83.65M | 54.06M |
| Common stock | 0.14M | 0.14M | 0.14M | 0.14M | 0.03M |
| Capital stock | 0.14M | 0.14M | 0.14M | 0.14M | 0.03M |
| Retained earnings | -3853.63500M | -3199.94600M | -2228.71300M | -1418.16000M | -946.46400M |
| Other liab | - | 4.12M | 11.78M | 0.49M | 0.99M |
| Good will | - | 1.82M | - | - | - |
| Other assets | - | 26.00M | 45.14M | 23.02M | 10.95M |
| Cash | 615.10M | 905.45M | 1431.32M | 1895.31M | 94.23M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 263.36M | 411.45M | 372.18M | 241.53M | 164.44M |
| Current deferred revenue | 131.73M | 149.44M | 143.84M | 75.52M | 53.64M |
| Net debt | -602.77200M | -854.66400M | -1344.63200M | -1848.42700M | -26.76100M |
| Short term debt | 8.63M | 37.24M | 37.37M | 46.88M | 44.39M |
| Short long term debt | - | - | 2.37M | 42.06M | 39.50M |
| Short long term debt total | 12.32M | 50.79M | 86.69M | 46.88M | 67.47M |
| Other stockholder equity | 4783.44M | 4523.87M | 4280.96M | 4006.62M | 45.64M |
| Property plant equipment | - | 300.03M | 406.44M | 111.48M | 89.31M |
| Total current assets | 884.10M | 1258.76M | 1820.95M | 2523.65M | 706.79M |
| Long term investments | 0.34M | 0.69M | 0.91M | 1.42M | 40.16M |
| Net tangible assets | - | 1156.36M | 1840.16M | 2417.55M | -891.83700M |
| Short term investments | 13.40M | 0.00000M | 63.76M | 362.13M | 313.99M |
| Net receivables | 167.81M | 151.71M | 134.59M | 110.96M | 208.55M |
| Long term debt | - | - | - | - | 18.27M |
| Inventory | 69.02M | 130.32M | 123.21M | 68.02M | 58.12M |
| Accounts payable | 18.06M | 50.95M | 63.08M | 35.48M | 12.35M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -161.53300M | -165.72200M | -207.06900M | -167.58900M | 9.30M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.14M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5.09M | 26.00M | 45.14M | 23.02M | 10.95M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 155.91M | 328.70M | 457.64M | 139.38M | 140.77M |
| Capital lease obligations | 12.32M | 50.79M | 84.31M | 4.82M | 9.71M |
| Long term debt total | - | - | - | - | 23.08M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -7.46300M | 81.70M | -30.42000M | -346.66000M | 106.09M |
| Change to liabilities | 22.06M | 63.10M | 49.98M | -10.62600M | 31.46M |
| Total cashflows from investing activities | -7.46300M | 81.70M | -109.31200M | -346.66000M | 106.09M |
| Net borrowings | -2.37000M | -44.80600M | -20.59400M | -81.59800M | 82.89M |
| Total cash from financing activities | -86.23800M | -52.89900M | 2165.72M | 571.74M | 83.39M |
| Change to operating activities | 30.60M | -8.73200M | 109.73M | -45.57300M | -10.17100M |
| Net income | -971.23300M | -796.69700M | -407.23500M | -169.15600M | -177.49700M |
| Change in cash | -513.84400M | -486.09400M | 1826.96M | 2.91M | 40.55M |
| Begin period cash flow | 1439.11M | 1925.21M | 98.24M | 95.33M | 54.79M |
| End period cash flow | 925.27M | 1439.11M | 1925.21M | 98.24M | 95.33M |
| Total cash from operating activities | -456.80800M | -477.88600M | -73.54300M | -228.04100M | -148.78000M |
| Issuance of capital stock | 0.00000M | 0.00000M | 2121.85M | 657.49M | 2.00M |
| Depreciation | 124.10M | 47.77M | 33.31M | 31.36M | 24.68M |
| Other cashflows from investing activities | - | 81.70M | -109.31200M | -109.31200M | -109.31200M |
| Dividends paid | - | - | -360.44100M | - | - |
| Change to inventory | 11.20M | -66.99900M | -9.44400M | -8.12200M | -32.25100M |
| Change to account receivables | -21.50500M | -18.93000M | -13.04200M | -65.94700M | 4.16M |
| Sale purchase of stock | -71.83400M | -4.27000M | -3.50000M | -4.15900M | -1.50000M |
| Other cashflows from financing activities | -12.03400M | -3.82300M | 721.58M | 672.21M | 98.61M |
| Change to netincome | 401.49M | 318.81M | 188.29M | 40.22M | 10.20M |
| Capital expenditures | 62.03M | 213.45M | 79.54M | 45.73M | 24.71M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 6.33M | -62.39500M | 112.10M | -130.46400M | -6.16100M |
| Stock based compensation | 326.78M | 282.43M | 173.22M | 22.79M | 5.09M |
| Other non cash items | 57.22M | 35.61M | 15.07M | 1.81M | 3.74M |
| Free cash flow | -518.83900M | -691.33400M | -153.08200M | -273.77500M | -173.49500M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNR Burning Rock Biotech Ltd |
-0.1 3.45% | 2.80 | - | - | 0.15 | 0.65 | 0.0032 | 0.01 |
| TMO Thermo Fisher Scientific Inc |
-9.29 2.13% | 427.50 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-3.83 2.01% | 186.83 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-0.22 0.21% | 102.48 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
9.11 2.26% | 411.49 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
No. 5, Xingdao Ring Road North, Guangzhou, China, 510005
| Name | Title | Year Born |
|---|---|---|
| Dr. Shaokun Chuai | Chief Scientific Officer & Director | 1979 |
| Mr. Yusheng Han | Founder, Chairman & CEO | 1979 |
| Mr. Jinxiang Li | CFO, Compliance Officer & Director | 1985 |
| Dr. Zhihong Zhang | Chief Technology Officer | 1976 |
| Mr. Hao Liu | Sr. Advisor | 1974 |
| Dr. Zhihong Zhang | CTO & Director | 1976 |
| Mr. Hao Liu | Senior Advisor | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...